To help support UCSF researchers in their drug and device development activities, the Early Translational Research group at UCSF’s CTSI has assessed and pre-selected a number of Contract Research Organizations (CROs) that offer a broad range of key research services. CROs offer specific expertise, capabilities and added capacity for various studies that are necessary to support translational research.
The CROs have been chosen on the basis of their proven technical expertise, flexibility, past experience in working with academic investigators, and price. The CROs have signed Master Service Agreements with the university (including a non-disclosure agreement), facilitating access of study directors by UCSF investigators to discuss study designs and to receive quotations.
Currently pre-selected CROs offer a broad spectrum of expertise and services, including (but not limited to):
- High-throughput screening
- ADME (in vitro and in vivo)
- Pharmacokinetics and pharmacodynamics
- Toxicology (including GLP tox)
- Bio/analytical services
- Medicinal Chemistry and custom synthesis
- GMP manufacturing
- Preclinical disease models
- Biocompatibility (for device development)
Additional CROs with device development expertise are currently being identified.